> For the complete documentation index, see [llms.txt](https://docs.owkin.com/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://docs.owkin.com/what-you-can-do-with-k-pro/trial-navigator-1/navigate-clinical-trials.md). # Navigate clinical trials ## What is Trial Navigator? Trial Navigator is a specialized agent in Owkin K that helps pharmaceutical and clinical teams explore the clinical trial landscape using plain-language questions. You ask the way you'd ask a colleague; it interprets the intent, filters a large clinical-trials dataset, and returns the right output: a visual timeline, a data table, a statistical projection, or a direct answer. Use it to: * **Map competitive landscapes** across an indication, mechanism of action, or drug class * **Track competitor pipelines** and development timelines * **Answer quantitative questions** about the trial landscape (counts, averages, distributions) * **Compare trials** against a reference trial (e.g. "PFS better than trial X") * **Deep-dive a single trial's** design assumptions and projected readout times ## How it works You don't need to know the internals to use Trial Navigator, but a quick mental model helps you write better queries. Behind the scenes it: {% stepper %} {% step %} ### Plans Breaks a complex question into sub-questions and, when needed, runs them in sequence, so "find trials better than X" first finds X, then compares the rest of the landscape against it. {% endstep %} {% step %} ### Translates Turns your words into structured filters: indication, phase, sponsor, dates, mechanism of action, enrollment thresholds, and more. {% endstep %} {% step %} ### Reconciles terminology Maps your wording to the dataset's standard names via a built-in thesaurus, so "immunotherapy", "IO", and "PD-1 inhibitor" resolve to the right underlying terms. {% endstep %} {% step %} ### Answers Returns a Gantt chart and table, a statistical projection, and/or a written summary, depending on what you asked for. {% endstep %} {% endstepper %} {% hint style="info" %} You can be conversational and use common abbreviations, the tool is designed to resolve them. The more specific you are, the sharper the result. {% endhint %} ## See it in action {% embed url="" %} ## Writing effective queries * Name the **therapeutic area / indication** (e.g. NSCLC, TNBC, glioblastoma). * Name the **mechanism of action or drug class** when relevant (PD-1/PD-L1, EGFR TKI, ADC, VEGFR, CLDN18.2). * Name **sponsors, drugs, or NCT IDs** when you have them. * Add a **phase** to narrow the development stage (Phase I, II, III, I/II…). * Add a **timeframe** ("started after 2020", "between 2018 and 2023"). * Add **thresholds** ("enrollment greater than 500", "accrual target of exactly 500"). * Use **exclusions** freely ("excluding Phase I", "excluding breast and prostate cancer"). * Ask for **top / latest / longest** when you want a ranked shortlist ("the 5 most recent…", "longest-running…"). ## What you can ask ### Competitive landscape / list trials Returns an interactive Gantt chart, a detailed results table, and summary statistics. ``` What are the clinical trials for immunotherapy in lung cancer? Show me immunotherapy trials for breast cancer started in 2020 or later. Find PD-1 or PD-L1 antagonist trials for colorectal cancer Find EGFR tyrosine kinase inhibitor trials for lung cancer in Europe Show me all Phase 1/2 studies for CLDN18.2 ADCs Show me gene therapy trials for glioblastoma started after 2018 ``` ### Complex multi-filter queries The tool handles several constraints at once, combining indication, phase, geography, dates, mechanism, and thresholds. ``` Find Phase II and III immuno-oncology trials for breast or lung cancer in Europe or North America, started between 2018-2023, with enrollment at least 500 patients Show me VEGFR tyrosine kinase inhibitor trials for prostate or colorectal cancer in Asia, started between 2010-2020, excluding Phase I trials Show me all Phase 3 Merck & Co. studies in NSCLC evaluating ADCs Chart all Roche P3 studies for atezolizumab in TNBC that have published data ``` ### Ranked / "top N" / "latest N" / "longest-running" Ask for a ranked shortlist instead of the full set. ``` Show me the 5 most recent AstraZeneca-sponsored clinical trials What are the longest-running clinical trials for melanoma? Show me recent small trials with high objective response rate ``` ### Aggregate & quantitative questions For counts, averages, percentages, and "what's covered" questions, the tool answers directly in text, with supporting figures where useful. ``` How many clinical trials are there for lung cancer started between 2015 and 2024? How many trials are sponsored by Roche that started in 2020? What is the average accrual target for Phase III trials? What percentage of ADC trials are Phase III? What is the most common indication for HER2-targeting ADC clinical trials? ``` ### Comparative queries (against a reference trial) The tool can find a reference trial first, then compare the rest of the landscape against it. ``` Find trials with progression-free survival greater than trial NCT00490139 Find trials with overall survival greater than trial NCT00490139 for breast cancer ``` ### Single-trial statistical analysis Deep-dive the statistical assumptions behind a specific trial's design and projected readout times. Returns a projection plot, predicted median OS/PFS, predicted enrollment duration, and the reference trials used for the prediction. ``` Show me the details for trial NCT00490139 Perform a statistical analysis for trial NCT00338247 What are the underlying assumptions for read out times of trial NCT00490139? ``` ## Understanding the outputs ### Gantt chart (timeline) * **X-axis:** time (years) * **Y-axis:** individual trials, grouped by phase and sorted by start date * **Colour:** trial phase; bars show duration with mechanism-of-action abbreviations * Includes both industry-sponsored and publicly/academically sponsored trials.
### Results table A sortable, filterable list of every matching trial: NCT ID (linked to [ClinicalTrials.gov](http://clinicaltrials.gov)), sponsor, phase, indication, drug/mechanism, and key results.
### Summary statistics An automatically computed answer summary, for example total trial count, phase distribution, and top indications represented.
### Statistical projection plot For single-trial analysis: an enrollment curve and survival projections, with the reference trials (by NCT ID) used to generate the predictions.
### PowerPoint export Trial Navigator can export a competitive-landscape view into a PowerPoint slide. {% hint style="info" %} PowerPoint export is a newer, deployment-gated capability, availability depends on your K environment. {% endhint %} ## Searchable data fields Trial Navigator is built on a comprehensive **oncology** clinical-trials dataset sourced from ClinicalTrials.gov. You can filter and search across the following dimensions. ### Identification | Field | Description | | --------------- | ---------------------------------------------------------- | | NCT ID | [ClinicalTrials.gov](http://clinicaltrials.gov) identifier | | Brief Title | Short trial title | | Official Title | Full formal trial title | | Commercial Name | Sponsor's commercial trial name | ### Status & timeline | Field | Description | | ----------------------- | -------------------------------------------------------------- | | Overall Status | Recruiting, Active Not Recruiting, Completed, Terminated, etc. | | Trial Start Date | Date the trial began | | Primary Completion Date | Date of primary outcome measurement | | Completion Date | Full study completion date | | Trial Duration | Duration in days | ### Design | Field | Description | | -------------- | --------------------------------------------------------- | | Study Type | Interventional, Observational | | Trial Phase | I, II, III, IV, I/II, II/III, III/IV | | Randomization | Whether the trial is randomized | | Number of Arms | Count of treatment arms | | Group Types | Experimental, Active Comparator, Placebo Comparator, etc. | ### Sponsors | Field | Description | | --------------------------- | ----------------------------------------------------------------------- | | Private / Industry Sponsors | Pharmaceutical and biotech companies (Pfizer, Roche, AstraZeneca, etc.) | | Public / Academic Sponsors | Universities, hospitals, research centers, government agencies | | Industry Sponsored | Boolean flag for industry involvement | ### Enrollment & accrual | Field | Description | | ------------------- | ---------------------------------- | | Enrollment | Number of participants | | Accrual Target | Target number of subjects | | Accrual Actual | Actual enrolled subjects | | Enrollment Duration | Time to complete enrollment (days) | ### Geography | Field | Description | | --------------- | --------------------------------------------------- | | Trial Countries | Countries where the trial is conducted | | Trial Regions | Regions (North America, Western Europe, Asia, etc.) | | Number of Sites | Count of trial sites | ### Eligibility criteria | Field | Description | | ---------------- | --------------------------------------------------------------------------- | | Gender | Both, Female Only, Male Only | | Age Range | Minimum and maximum age for eligibility | | ECOG Status | Performance status requirements (0-4 scale) | | Disease Stages | Localized, locally advanced, advanced, metastatic, resectable, unresectable | | Disease Paths | Persistent, recurrent, refractory, relapsed, resistant | | Lines of Therapy | Prior treatment requirements | ### Indications (cancer types) Trial Navigator covers a comprehensive oncology landscape, including: **Solid tumors:** * Breast, Lung (NSCLC, SCLC), Colorectal, Pancreas * Melanoma, Renal, Bladder, Prostate * Head/Neck, Esophageal, Gastric, Liver * Ovarian, Endometrial, Cervical * CNS tumors (Glioblastoma, Astrocytoma, Meningioma, etc.) * And many more **Hematological malignancies:** * Leukemia (ALL, AML, CML, CLL) * Lymphoma (Hodgkin's, Non-Hodgkin's) * Multiple Myeloma * Myelodysplastic Syndrome * Myeloproliferative Neoplasms ### Treatment & intervention | Field | Description | | -------------------- | ------------------------------------------------------------------------------ | | Drug Names | Investigational drug names | | Drug Type | ADC, Antibody Bispecific, Antibody Multispecific, Gene Therapy, Small Molecule | | Mechanisms of Action | JAK inhibitor, CDK inhibitor, PD-1/PD-L1 inhibitor, etc. | | Targets (HGNC) | Gene symbols (KRAS, TP53, BRCA1, EGFR, ERBB2, etc.) | | Biomarkers | Biomarkers used in trial selection | | Combination Therapy | Whether the trial tests a drug combination | ### Endpoints | Field | Description | | ----------------- | -------------------------------------------------- | | Primary Endpoints | OS, PFS, DUAL, or other | | Has OS | Overall Survival as endpoint | | Has PFS | Progression-Free Survival as endpoint | | Has EFS/DFS/RFS | Event-free, Disease-free, Recurrence-free Survival | ### Outcomes (actual & predicted) | Field | Description | | ----------------------------- | ---------------------------------------- | | Objective Response Rate | ORR from trial results | | Disease Control Rate | DCR from trial results | | Median OS (months) | Actual median overall survival | | Median PFS (months) | Actual median progression-free survival | | Predicted Median OS | AI-predicted median OS | | Predicted Median PFS | AI-predicted median PFS | | Predicted Enrollment Duration | AI-predicted time to complete enrollment | ## Tips & good-to-knows {% hint style="info" %} * **Be conversational, but specific.** Abbreviations and synonyms are resolved by the thesaurus; specificity narrows results. * **Smart name resolution.** The tool understands common synonyms and variations, for example "Keytruda" maps to pembrolizumab, "Herceptin" to trastuzumab, gene-name variants (ERBB2 / HER2 / neu), and sponsor name variations (Merck & Co., MSD, Merck Sharp & Dohme). * **Large landscapes are shown, not silently truncated.** The chart focuses on the most relevant trials for readability while the underlying query covers the full matching set. If a very large landscape is capped for display, the tool tells you. * **Statistical projections are model-based estimates**, derived from historically comparable reference trials. Treat them as directional, not definitive, and note they are available only for Phase II and III trials with sufficient historical data. * **Coverage is oncology-focused.** Non-oncology questions may return limited or no results. * **Data reflects ClinicalTrials.gov**, so completeness depends on what sponsors have registered and published. For real-time status, verify directly on [ClinicalTrials.gov](http://clinicaltrials.gov). {% endhint %} --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://docs.owkin.com/what-you-can-do-with-k-pro/trial-navigator-1/navigate-clinical-trials.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.